This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DEPO Depomed (DEPO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Depomed Stock (NASDAQ:DEPO) 30 days 90 days 365 days Advanced Chart Get Depomed alerts:Sign Up Key Stats Today's Range$7.09▼$7.4250-Day Range N/A52-Week Range$4.31▼$9.48Volume940,193 shsAverage Volume1.30 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAssertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.Read More… Receive DEPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Depomed and its competitors with MarketBeat's FREE daily newsletter. Email Address DEPO Stock News HeadlinesPfizer: Investor Activism Is Not The SolutionOctober 9, 2024 | seekingalpha.comNeuropathic Pain Market Demand to Hit USD 13.16 Billion by 2033 | Globally at 5.55% CAGRSeptember 5, 2024 | finance.yahoo.comVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.May 3, 2025 | Stansberry Research (Ad)Vulvodynia Treatment Market Size and Growth Analysis | Future Trends Analysis and Revenue Status 2023-2030October 30, 2023 | finance.yahoo.comHorizon Pharma (HZNP) Stock Sinks After DepoMed Rejects Unsolicited $3 Billion BidAugust 29, 2023 | thestreet.comWhy DepoMed (DEPO) Stock Is Gaining TodayAugust 13, 2023 | thestreet.comSurge in Chronic Disorders Fuels Expansion of Global Tapentadol Market, Projected to Hit USD 5.32 Billion by 2028July 31, 2023 | finance.yahoo.comOpioid Litigants Get Boost From Senate ReportJuly 8, 2023 | thestreet.comSee More Headlines DEPO Stock Analysis - Frequently Asked Questions How were Depomed's earnings last quarter? Depomed, Inc. (NASDAQ:DEPO) released its earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.03. The business's quarterly revenue was down 37.0% compared to the same quarter last year. What other stocks do shareholders of Depomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Depomed investors own include Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY), MercadoLibre (MELI), Alphabet (GOOG), Horizon Therapeutics Public (HZNP) and Bausch Health Companies (BHC). Company Calendar Last Earnings8/08/2018Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DEPO CIK1005201 Webwww.depomedinc.com Phone(224) 419-7106FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:DEPO) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Depomed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Depomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
